Take a look at our previous reports:

Annual Report

2015

View Report

Q1 Report

2016

View Report

H1 Report

2016

View Report

Q3 Report

2016

View Report
English | Dutch
Jump to content [AK + s] Jump to navigation [AK + 3]

Annual Report 2016

  • Twitter
  • LinkedIn

Primary Menu

  • The Galapagos group
    • Letter from the management
    • Committed to moving forward
      • Walid Abi-Saab
      • Ellen van der Aar
      • Veronique Deiteren
    • At a glance
    • Strategy
    • Going concern statement
    • Risk management and internal control
    • The Galapagos share
    • Subsequent events
    • Overview of Galapagos NV
    • Disclaimer and other information
  • R&D
    • The Galapagos pipeline
    • Target discovery platform
    • Rheumatoid arthritis
      • Filgotinib program in RA
    • Inflammatory bowel disease
      • Filgotinib program in IBD
      • Clinical program with filgotinib in CD
      • Clinical program with filgotinib in UC
    • Cystic fibrosis
      • Clinical program for CF
    • Idiopathic pulmonary fibrosis
    • Osteoarthritis
    • Atopic dermatitis
  • Risk factors
    • Financial position and need for additional capital
    • Product development, regulatory approval and commercialization
    • Reliance on third parties
    • Competitive position
    • Intellectual property
    • Organization, structure and operation
    • Galapagos shares
    • General statement
  • Corporate governance
    • Policies
    • Board of directors
    • Committees
    • Share capital and shares
    • Shareholders
    • Remuneration report
      • Determination of remuneration
      • Remuneration policy
      • Non-executive directors
      • Executive directors
      • Criteria and methods to evaluate performance
      • Gross remuneration of CEO
      • Gross remuneration of other executive committee members
      • Shares, warrants or other rights
      • Severance payments
      • Severance payments in 2016
      • Claw-back right
    • Conflict of interests and related parties
    • Statement by the board of directors
  • Financial statements
    • Consolidated financial statements
      • Statements of income and comprehensive income
      • Statements of financial position
      • Cash flow statements
      • Statements of changes in equity
    • Notes to the consolidated financial statements
      • Notes 1-10
        • 1. General information
        • 2. Significant accounting policies
        • 3. Critical accounting estimates and judgments
        • 4. Segment information
        • 5. Total revenues and other income
        • 6. Operating costs
        • 7. Staff costs
        • 8. Fair value re-measurement of share subscription agreement
        • 9. Other financial income/expenses
        • 10. Taxes
      • Notes 11-20
        • 11. Result per share
        • 12. Intangible assets
        • 13. Property, plant and equipment
        • 14. Other non-current assets
        • 15. Research and Development incentives receivables
        • 16. Restricted cash
        • 17. Trade and other receivables and other current assets
        • 18. Cash and cash equivalents
        • 19. Share capital
        • 20. Other reserves
      • Notes 21-30
        • 21. Translation differences
        • 22. Deferred tax
        • 23. Finance lease liabilities
        • 24. Trade and other liabilities
        • 25. Provisions
        • 26. Operating lease obligations
        • 27. Off-balance sheet arrangements
        • 28. Contingent assets and liabilities
        • 29. Retirement benefit plans
        • 30. Warrant plans
      • Notes 31-35
        • 31. Related parties
        • 32. Consolidated companies as of 31 December 2016
        • 33. Financial risk management
        • 34. Statutory auditor’s remuneration
        • 35. Events after balance sheet date
    • Non-consolidated financial statements
  • Auditor's report
    • Report of the statutory auditor

You are here:

  • Home
  • Glossary of terms
  • HDL
HDL

HDL

High-density lipoprotein. HDL scavenges and reduces low-density lipoprotein (LDL) which contributes to heart disease at high levels. High levels of HDL reduce the risk for heart disease, while low levels of HDL increase the risk of heart disease*

* Source: webmd.com/cholesterol-management/guide/hdl-cholesterol-the-good-cholesterol#1
Download Center
to page top

Service

  • Glossary of terms
  • Downloads
  • Financial calendar
  • Galapagos Corporate Website

Last Update 23 March 2017

Galapagos Annual Report 2016 (PDF)

Download the entire report as PDF.

Download PDF (3.3 MB)
English | Dutch
  • Downloads
  • Glossary of terms
  • © Copyright 2017 Galapagos NV
  • Colophon
  • Contact
  • Sitemap
© Copyright 2017 Galapagos NV
nexxar - digital reporting evolved - Online Report